AnaptysBio, Inc. ANAB 深 沪
等待开盘 05-12 09:30:00 美东时间
67.565
-1.765
-2.55%
华盛通- 最 高72.2299
- 今 开69.75
- 成交量 29.94万股
- 最 低 62.07
- 昨 收 69.33
- 总市值 190.44万
- 52周最高 73.30
- 市盈率 静 --
- 换手率 1062.30%
- 52周最低 17.1062
- 委 比 33.33%
- 总股本 2.82万
- 历史最高 134.00
- 量 比 0.64
- 振 幅 14.65%
- 历史最低 1.10
- 每 手 1
- 风险率 15.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AnaptysBio Appoints Christopher Murphy CFO
AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial
05-11 21:16
AnaptysBio Wins Court Ruling Upholding Jemperli Royalties, Trial Vs. Tesaro/GSK Set For July 14–17, 2026
Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reductionTrial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled
04-25 03:43
AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties
AnaptysBio asks a Delaware court to dismiss Tesaro's breach claim, citing anti-SLAPP law in a dispute over Jemperli royalties and licensing rights.
01-10 02:56
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
GSK's Tesaro sues AnaptysBio over alleged Jemperli contract breaches, putting royalties, milestones, and future licensing rights into question.
2025-11-21 21:48
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study
AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs.
2025-11-11 01:30
迎接PD-1激动剂的热潮
（来源：氨基观察） PD-(L)1这座宝矿还有更多等待挖掘… 当PD-1抑制剂还在肿瘤领域续写“药王”传奇时，PD-1激动剂已悄然展现出改写自身免疫病治疗格局...
2025-10-09 10:29
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
Rosnilimab, a novel PD-1-targeting antibody, demonstrated Jak-like efficacy and favorable safety in a Phase 2b study for moderate-to-severe rheumatoid arthritis. The therapy achieved low disease activity and ACR50 responses with monthly dosing, and responses were durable for at least two months off treatment. AnaptysBio will host a conference call today to discuss the results.
2025-06-03 20:05
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
AnaptysBio will host an investor call on June 3, 2025, at 4:15pm ET / 1:15pm PT to discuss updated Phase 2b RENOIR trial data for rosnilimab, with experts Paul Emery and Jonathan Graf. Live webcasts and replays will be available on its website. The company’s executives will also attend the Jefferies Global Healthcare Conference on June 5 and the Goldman Sachs Global Healthcare Conference on June 11.
2025-05-27 20:15
【国金医药·行业周报】2025医药投资战略布局创新成长，“AI+创新药”两手抓
投资逻辑： 本周医药生物板块在申万各一级行业中表现较强，其中AI相关医药标的热度持续提升。我们认为，随着AI医疗的崛起和产业快速跟进，2025年医药投资迎来重大...
2025-02-16 21:58
礼来终止PD-1激动剂候选药物研究 AnaptysBio暴跌超20%
周三，AnaptysBio（ANAB.US）股价走低，截至发稿，该股跌超20%，报24.455美元。AnaptysBio正在推进一种与礼来（LLY.US）PD-1激动剂抗体Peresolimab类似的关节炎疗法，在礼来宣布决定终止对该候选药物的研究后，AnaptysBio股价大跌。 今年7月，H.C． Wainwright首次覆盖AnaptysBio，给予“买入”评级和55美元的目标价。该行认为其旗下的PD-1激动剂rosnilimab可能比peresolimab更有效。rosnilimab的试验初步数据预计将在2025年第一季度公布。 海量资讯、精准解读，尽在新浪财经APP 责任编辑...
2024-10-30 22:26
